Immunopharmacological effects of Rituximab in atopic dermatitis

Journal of Drugs in Dermatology, April, 2006

This study is currently recruiting patients. Verified by University of Bern. Sponsors and Collaborators: University of Bern, Roche, Swiss National Science Foundation. Primary Study Objective: to determine the efficacy, safety and immunopharmacological effects of Rituximab (anti-CD20) administered as a 1000mg intravenous infusion on days 1 and 15 to patients with atopic dermatitis. Secondary Study Objective: to investigate key immunological parameters involved in the pathology of this common skin disease to interpret the clinical findings.

Condition           Intervention

Dermatitis, Atopic  Drug: Rituximab

Study ID Numbers: 2005 DR 3297; Roche Pharma AG, Switzerland

ClinicalTrials.gov Identifier: NCT00267826